The impact of pharmacist early active consultation (PEAC) on multidrug resistance organism treatment outcomes: A prospective historically controlled study

作者全名："Du, Qian; Xi, Xin; Dong, Jie; Zhang, Tongyan; Li, Dongxuan; Dong, Yuzhu; Li, Wenjun; Huang, Guili; Zhu, Jun; Ran, Hailong; Gou, Jinghui; Chen, Cheng; Bai, Zhanfeng; Liu, Qinglong; Yao, Wei; Zhang, Lei; Bi, Yutian; Liu, Songqing"

作者地址："[Du, Qian; Xi, Xin; Dong, Jie; Li, Dongxuan; Dong, Yuzhu; Li, Wenjun; Huang, Guili; Zhu, Jun; Ran, Hailong; Gou, Jinghui; Chen, Cheng; Bai, Zhanfeng; Liu, Qinglong; Liu, Songqing] Chongqing Med Univ, Affiliated Hosp 3, Dept Pharm, Chongqing, Peoples R China; [Zhang, Tongyan] Tianjin Univ Tradit Chinese Med, Affiliated Hosp 2, Infect Dis Dept, Tianjin, Peoples R China; [Li, Dongxuan] Chongqing Med Univ, Coll Pharm, Chongqing, Peoples R China; [Yao, Wei] Chongqing Med Univ, Affiliated Hosp 3, Dept Resp Med, Chongqing, Peoples R China; [Zhang, Lei] Chongqing Med Univ, Affiliated Hosp 3, Dept Intens Care Unit, Chongqing, Peoples R China; [Bi, Yutian] Chongqing Med Univ, Affiliated Hosp 3, Dept Med Adm, Chongqing, Peoples R China"

通信作者："Liu, SQ (通讯作者)，Chongqing Med Univ, Affiliated Hosp 3, Dept Pharm, Chongqing, Peoples R China.; Bi, YT (通讯作者)，Chongqing Med Univ, Affiliated Hosp 3, Dept Med Adm, Chongqing, Peoples R China."

来源：FRONTIERS IN PHARMACOLOGY

ESI学科分类：PHARMACOLOGY & TOXICOLOGY

WOS号：WOS:000952447100001

JCR分区：Q1

影响因子：4.4

年份：2023

卷号：14

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：clinical pharmacists; infective disease; consultation; multidrug-resistance organism; early intervention

摘要："Background and aim: Infectious disease (ID) consultation can improve multidrug-resistant organism (MDRO) treatment outcomes. However, the impact of clinical pharmacists' ID consultation on MDRO therapy, especially early initiation, has not been reported. In this study, we try to explore the impact of the pharmacist early active consultation (PEAC) on MDRO patient management.Methods: We conducted a prospective historical controlled study based on PEAC in MDRO patients. The retrospective control group was patients hospitalized 18 months before the PEAC initiation, and the prospective PEAC group was patients hospitalized 18 months after the PEAC initiation. Primary endpoint was 30-day all-cause mortality. Secondary outcomes were MDRO clinical outcome, duration of antibiotic use, length of stay, antibiotic consumption and antibiotic costs. Further subgroup analysis of secondary outcomes was performed by the condition at admission, MDRO pathogenicity and MDRO clinical outcome.Results: 188 MDRO patients were included. After adjusting for potential predictors, PEAC reduced the 30-day all-cause mortality by 70% (HR 0.30, 95% CI 0.09-0.96, p = 0.042). PEAC group had clinical improvement than control group (89.47% vs. 65.59%, p < 0.001), especially in patients with non-severe clinical conditions at admission (98.41% vs. 70.18%, p < 0.001). However, no significant differences were found between groups in length of stay, antibiotics consumption, and antibiotics costs.Conclusion: Early active pharmacy ID consultation can reduce 30-day all-cause mortality and improve clinical outcomes in MDRO patients."

基金机构："Chongqing Science and Technology Commission [cstc2019jscx-msxmX0195]; Science and Technology Commission of Yuzhong District of Chongqing [20190113]; Incubation Program of the Third Affiliated Hospital of Chongqing Medical University, China [KY22038]"

基金资助正文："This study was supported by the Application and Development Project from Chongqing Science and Technology Commission (No. cstc2019jscx-msxmX0195), the Scientific Research Program of Science and the Science and Technology Commission of Yuzhong District of Chongqing (No. 20190113) and the Incubation Program of the Third Affiliated Hospital of Chongqing Medical University, China (KY22038)."